ACT-001 is under clinical development by Accendatech and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According to GlobalData, Phase II drugs for Recurrent Glioblastoma Multiforme (GBM) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ACT-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ACT-001 overview

ACT-001 is under development for the treatment of progressing fibrosing interstitial lung disease and idiopathic pulmonary fibrosis, brain metastases from small cell lung cancer and non-small cell lung cancer, glioblastoma multiforme, pediatric diffuse intrinsic pontine glioma and recurrent optic neuromyelitis lineage-associated optic neuritis. It is administered orally. The drug candidate is dimethylaminomicheliolide (DMAMCL), a micheliolide (MCL) derivative. It was also under development for refractory acute myeloid leukemia. It acts by targeting STAT3, NFKB , PAI-1 and PKM2.

It was also under development for the treatment of solid tumors including colorectal cancer, primary non-small cell lung carcinoma, breast cancer, head and neck cancer, urogenital cancer, hepatocellular carcinoma, malignant melanoma,

For a complete picture of ACT-001’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.